BCL2 and acute myeloid leukemia: Venetoclax, an oral selective inhibitor of the anti-apoptotic protein B-cell leukemia/lymphoma 2 (BCL-2), in combination with HMAs has worked effectively in preclinical models, suggesting that this is an effective treatment for AML (20).